Pomalidomide therapy for myeloma

Bibliography

• Speirs AL. Thalidomide and congenital abnormalities. Lancet 1962;20(7224):303-5
   Google Scholar
• Hagen EO. Drugs and congenital abnormalities. Lancet 1963;1(7279):501
   PubMedGoogle Scholar
• Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-6
   PubMed Web of Science ®Google Scholar
• Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187(11):1885-92
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173(3):699-703
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5
   PubMed Web of Science ®Google Scholar
• Solly S. Remarks on the pathology of mollities ossium with cases. Med Chir Trans Lond 1844;27:435-61
   PubMedGoogle Scholar
• Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10(2):334-42
   PubMed Web of Science ®Google Scholar
• Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma. an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998;16(12):3832-42
   PubMedGoogle Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516-20
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O, Dickman PW, Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25(15):1993-9
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111(5):2521-6
   PubMed Web of Science ®Google Scholar
• Barlogie B, Velasquez WS, Alexanian R, Cabanillas F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 1989;7(10):1514-17
   PubMed Web of Science ®Google Scholar
• Barlogie B, Alexanian R. Therapy of primary resistant and relapsed multiple myeloma. Onkologie 1986;9(4):210-4
   PubMed Web of Science ®Google Scholar
• Alexanian R, Yap BS, Bodey GP. Prednisone pulse therapy for refractory myeloma. Blood 1983;62(3):572-7
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875-83
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335(2):91-7
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609-17
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108(10):3458-64
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-42
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892-901
   PubMed Web of Science ®Google Scholar
• Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114(27):5436-43
   PubMed Web of Science ®Google Scholar
• David Siegel LW, Orlowski RZ, Jonathan L, ; The Multiple Myeloma Research Consortium (MMRC). PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort. ASH: Blood ASH Annual Meeting Abstracts; 2009
   Google Scholar
• Luhua Wang DS, Jonathan L, Kaufman A, ; The Multiple Myeloma Research Consortium (MMRC). Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM). ASH: Blood ASH Annual Meeting Abstracts; 2009
   Google Scholar
• Ruben Niesvizky LW, Orlowski RZ, Bensinger W, ; The Multiple Myeloma Research Consortium (MMRC). Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). ASH: Blood ASH Annual Meeting Abstracts; 2009
   Google Scholar
• Kastritis E, Palumbo A, Dimopoulos MA. Treatment of relapsed/refractory multiple myeloma. Semin Hematol 2009;46(2):143-57
   PubMed Web of Science ®Google Scholar
• Blade J, Esteve J, Rives S, High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000;26(8):845-9
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4(4):314-22
   PubMed Web of Science ®Google Scholar
• Racanelli V, Leone P, Frassanito MA, Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood 2010;115(6):1185-93
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Pratt G, McLarnon A, Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood 2008;112(8):3362-72
   PubMed Web of Science ®Google Scholar
• Feyler S, von Lilienfeld-Toal M, Jarmin S, CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009;144(5):686-95
   PubMed Web of Science ®Google Scholar
• Jinushi M, Vanneman M, Munshi NC, MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008;105(4):1285-90
   PubMed Web of Science ®Google Scholar
• Pope B, Brown RD, Gibson J, B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 2000;96(4):1274-9
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Todryk SM, Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002;168(10):4914-19
   PubMed Web of Science ®Google Scholar
• Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57(12):1849-59
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210-16
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58(7):1033-45
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Mesa RA, Fonseca R, Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8(7):2210-16
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Ribatti D, A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003;88(2):176-85
   PubMedGoogle Scholar
• Kumar S, Witzig TE, Dispenzieri A, Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004;18(3):624-7
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140(1):36-45
   PubMed Web of Science ®Google Scholar
• Lu L, Payvandi F, Wu L, The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009;77(2):78-86
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69(18):7347-56
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99(12):4525-30
   PubMed Web of Science ®Google Scholar
• Sharma S, Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 2008;112(4):1338-45
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96(9):2943-50
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23(3):435-41
   PubMed Web of Science ®Google Scholar
• Melton LJ III, Kyle RA, Achenbach SJ, Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005;20(3):487-93
   PubMed Web of Science ®Google Scholar
• Anderson G, Gries M, Kurihara N, Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107(8):3098-105
   PubMed Web of Science ®Google Scholar
• Xu Y, Li J, Ferguson GD, Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009;114(2):338-45
   PubMed Web of Science ®Google Scholar
• Corral LG, Muller GW, Moreira AL, Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2(4):506-15
   PubMed Web of Science ®Google Scholar
• Ladetto M, Vallet S, Trojan A, Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005;105(12):4784-91
   PubMed Web of Science ®Google Scholar
• Prince HM, Mileshkin L, Roberts A, A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005;11(15):5504-14
   PubMed Web of Science ®Google Scholar
• Ferguson GD, Jensen-Pergakes K, Wilkey C, Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 2007;27(2):210-20
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB, Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269-76
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141(1):41-51
   PubMed Web of Science ®Google Scholar
• Paul Richardson DS, Baz R, Kelley SL, A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib [abstract no: 301]. ASH: Blood ASH meeting Abstracts; 2009
   Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(30):5008-14
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24(11):1934-9
   PubMed Web of Science ®Google Scholar
• Xavier Leleu MA, Moreau P, Duhamel A, ; Thierry Facon. Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02. Blood ASH Annual Meeting Abstracts; 2010
   Google Scholar
• Martha Lacy SM, Gertz MAA, Suzanne R, Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. ASH: Blood ASH Annual Meeting Abstracts; 2010
   Google Scholar
• Gertz MA, Kumar S, Lacy MQ, Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010;115(12):2348-53, quiz 560
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86
   PubMed Web of Science ®Google Scholar
• Kumar SK, Flinn I, Noga SJ, Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 2010;24(7):1350-6
   PubMed Web of Science ®Google Scholar
• Adams MSP, Bartlett JB. The anti-proliferative effect of lenalidomide on MM cells in vitro is ameliorated by prior exposure to pomalidomide, an agent with activity against lenalidomide resistant MM cells. ASH: Blood ASH Annual Meeting Abstracts; 2009
   Google Scholar
• Spencer A, Prince HM, Roberts AW, Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27(11):1788-93
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354(10):1021-30
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S, Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108(10):3289-94
   PubMed Web of Science ®Google Scholar
• Palumbo A, Gay F, Falco P, Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28(5):800-7
   PubMed Web of Science ®Google Scholar
• Maria-Victoria Mateos LL-C, Hernandez MT, de la Rubia J, San-Miguel. Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: results of the first interim analysis. ASH; 2009
   Google Scholar
• Rapoport AP, Aqui NA, Stadtmauer EA, Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination based on hTERT and survivin following ASCT for myeloma. Blood 2011;117(3):788-97
   Google Scholar
• Stadtmauer EA, Vogl DT, Luning Prak E, Transfer of influenza vaccine-primed co-stimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 2011;117:63-71
   Google Scholar
• Moutouh-de Parseval LA, Verhelle D, Glezer E, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008;118(1):248-58
   PubMed Web of Science ®Google Scholar